Autologous stem cell transplantation (ASCT) for primary systemic amyloidosis (AL) produces high hematologic and organ responses. However, treatment-related mortality remains high and reported series are subject to selection bias. In all, 48 of 80 amyloid patients referred to our center had AL in the absence of myeloma, 26 of these 48 were deemed transplant candidates and 20 actually underwent ASCT. Transplant-related mortality has fallen from 50 to 20% since January 1999 due to better patient selection and prophylactic measures. Intent-to-treat organ responses were renal (46%), cardiac (25%) and liver (50%). Organ responses in patients who survived transplantation were renal (75%), cardiac (40%) and liver (100%). The 3-year OS post-ASCT was 56% with improved outcome predicted by a better performance status (P ¼ 0.08), normal ALP (P ¼ 0.08), nephrotic syndrome (P ¼ 0.01) and the absence of severe hypotension (P ¼ 0.01). The 3-year OS for all referred patients was 44% and this was not significantly better for transplant candidates. Patients with significant hypotension (systolic blood pressure p90 mmHg) or poor performance status (ECOG 42) have an exceedingly high treatment-related mortality and should not be transplanted. For those undergoing ASCT, organ response rates appear promising, but conclusive evidence of improved survival for this select group of patients is still lacking and will require randomized trials.
Autologous stem cell transplantation (ASCT) for primary systemic amyloidosis (AL) produces high hematologic and organ responses. However, treatment-related mortality remains high and reported series are subject to selection bias. In all, 48 of 80 amyloid patients referred to our center had AL in the absence of myeloma, 26 of these 48 were deemed transplant candidates and 20 actually underwent ASCT. Transplant-related mortality has fallen from 50 to 20% since January 1999 due to better patient selection and prophylactic measures. Intent-to-treat organ responses were renal (46%), cardiac (25%) and liver (50%). Organ responses in patients who survived transplantation were renal (75%), cardiac (40%) and liver (100%). The 3-year OS post-ASCT was 56% with improved outcome predicted by a better performance status (P ¼ 0.08), normal ALP (P ¼ 0.08), nephrotic syndrome (P ¼ 0.01) and the absence of severe hypotension (P ¼ 0.01). The 3-year OS for all referred patients was 44% and this was not significantly better for transplant candidates. Patients with significant hypotension (systolic blood pressure p90 mmHg) or poor performance status (ECOG 42) have an exceedingly high treatment-related mortality and should not be transplanted. For those undergoing ASCT, organ response rates appear promising, but conclusive evidence of improved survival for this select group of patients is still lacking and will require randomized trials. Primary systemic amyloidosis (AL) is characterized by the extracellular deposition of insoluble monoclonal immunoglobulin light chain fragments in organs and tissues. As a plasma cell dyscrasia related to multiple myeloma, the pathologic AL protein is produced by clonal plasma cells in the bone marrow. 1, 2 The clinical manifestations are multiple and reflect the predominant organs involved with renal, cardiac, neurologic and hepatic dysfunction most commonly arising and inevitably leading to death. It is a rare disease with an estimated age-adjusted incidence of 5.1-12.8 cases per million person-years. 3 Prognosis is poor and has not changed over several decades with a median survival in the range of 12-18 months, 2,4,5 although a proportion of patients do become long-term survivors. 6 The clonal origins shared by AL and multiple myeloma have provided rationale for chemotherapy treatment. The value of melphalan and prednisone has been confirmed in three randomized trials, [7] [8] [9] although response rates are low and the survival benefit is small. More recently, high-dose melphalan with autologous hematopoietic stem cell transplantation (ASCT) has been applied to the management of patients with AL. While transplant-related mortality has been high, promising organ and hematologic response rates have been reported in addition to suggestions of improved overall survival. 10 Cohort studies of patients undergoing ASCT are, however, affected by selection bias. Transplant candidates are likely to be younger, healthier and have less severe organ dysfunction 11 making assessment of the benefit of ASCT difficult. Little information is available to guide the decision making process for these patients from the time of referral. This paper analyzes the outcome of all patients referred to our institution since the initiation of our AL transplant program, with particular attention to the impact of ASCT in the entire patient population.
Materials and methods

Patients
Consecutive patients with a diagnosis of AL were identified from the referral database of the Princess Margaret Hospital Myeloma Service. Only patients referred between the inception of the AL transplant program in September 1996 and December 2001 were considered. Data for this retrospective study were abstracted from the database, and patient medical records according to a protocol approved by the University Health Network Institutional Review Board.
Eligibility for transplantation
Following the initial diagnostic work-up, each patient's candidacy for transplantation was considered. In the hope of benefiting patients with the worst prognosis (particularly symptomatic cardiac AL), ASCT was initially offered to all patients except for those with age 465 years or ECOG performance status 43. Following review of our initial experience with stem cell mobilization and transplantation in this patient population, 12 additional selection criteria were introduced due to the high morbidity and mortality seen in patients with cardiac amyloid. From January 1999 onwards, stem cell transplantation was not offered to patients with syncope, cardiac interventricular wall thickness 415 mm and significant sustained hypotension (systolic blood pressure p90 mmHg).
Peripheral blood stem cell collection and transplantation
Peripheral blood stem cells were mobilized with cyclophosphamide 2.5 g/m 2 on day 1 and G-CSF 10 mg/kg/day from day 4 or with G-CSF 10 mg/kg/day alone. The minimum target CD34 þ cell count was 2 Â 10 ) melphalan i.v. on day -2 depending on the patient's age, renal function and performance status. Two patients treated early in our series with reduced-dose melphalan also received fractionated TBI 2 Gy twice daily on day -2 to 0 (total dose 12 Gy). Several measures were introduced in January 1999 to reduce therapy-related toxicity, particularly in patients with cardiac involvement. These included use of prophylactic antiarrhythmic agents, mobilization with growth factor alone, infusion of DMSO-depleted grafts, avoidance of radiation in the conditioning regimen and use of cardiac monitoring. 12 
Definitions
The diagnosis of AL required histopathological demonstration of amyloid together with evidence of plasma cell monoclonality (urine or serum monoclonal paraprotein, light chain restriction of bone marrow plasma cells or amyloid). Patients with hereditary or localized AL were excluded, as were patients with underlying lymphoma or myeloma, including those with 420% bone marrow plasmacytosis.
Organ involvement was similar to previous reports 13 and was defined as follows: renal, proteinuria 40.5 g/day and/ or biopsy proven renal involvement and/or raised creatinine in the absence of other causative factors; cardiac, echocardiogram demonstration of interventricular wall thickness 412 mm, infiltrative cardiomyopathy or diastolic dysfunction and/or history or clinical evidence of congestive heart failure in the absence of other causes; hepatic, alkaline phosphatase 41.5 times normal and/or clinically increased liver span; neurological, peripheral neuropathy (not including carpal tunnel syndrome) and/or autonomic neuropathy; other organ involvement was noted descriptively.
Organ-specific responses were defined as follows: hematologic, a complete response required o5% bone marrow plasma cells in addition to the absence of monoclonal paraprotein in the urine and serum as detected by immunofixation, a partial response required at least a 50% decrease in the bone marrow plasmacytosis together with a 50% decrease in any monoclonal paraprotein; renal, 50% decrease in 24 h proteinuria with a stable or improved creatinine; cardiac, reduction in interventricular wall thickness of X2 mm or improvement in New York Heart Association heart failure class; hepatic, 50% decrease in alkaline phosphatase or reduction in liver span of at least 2 cm; neurologic, resolution of symptoms and signs of peripheral neuropathy or normalization of postural hemodynamic instability. Other tissue involvement was not assessable for response. Organ responses refer to the best response seen in the post transplant period, with routine follow-up including three monthly clinical and laboratory assessments with echocardiography performed annually. Patients who died before assessment of response to ASCT were considered nonresponders.
Statistical analysis
End points included transplant-related mortality, organresponse rates and overall survival. Transplant-related mortality was defined as all deaths within 100 days post transplant. Patient and disease characteristics of transplant and nontransplant candidates were compared using the Fisher exact test for categorical variables and the Wilcoxon rank-sum for continuous variables. Overall survival was estimated using the method of Kaplan and Meier, both from the time of referral and from the time of transplantation. Variables analyzed for their impact on survival included patient characteristics (age, performance status), cardiac status (hypotension, left ventricular ejection fraction, cardiac failure, septal wall thickness, syncope), renal status (creatinine, nephritic syndrome), hepatic status (alkaline phosphatase), number of organs involved, prior therapy and transplant 'era' (pre vs post-January 1999). Cox proportion hazards were used for continuous variables and the log-rank test was used for categorical variables. Summary statistics use median values with ranges or 95% confidence intervals in brackets. Statistical analysis was performed using the STATA (University of Texas) statistical software package.
Results
Patient characteristics
A total of 80 patients with symptomatic amyloid disease were referred to our institution. Of these, 32 patients who did not have AL were excluded from analysis on the basis of clinical but not biopsy evidence of amyloid (n ¼ 4), hereditary or localized amyloid (n ¼ 5) and coexistent lymphoma (n ¼ 3) or multiple myeloma (n ¼ 20) . The characteristics at referral of the 48 patients with AL considered in this study are detailed in Table 1 , which compares the patients according to whether or not they were considered candidates for autologous transplantion. The pathological demonstration of amyloid was obtained from renal (n ¼ 16), rectal (n ¼ 10), cardiac (n ¼ 6), liver (n ¼ 3) and other biopsies including bone marrow, tongue, lymphadenopathy and abdominal fat pad (n ¼ 13). The monoclonal light chain was of lambda type in 65% of cases and 78% had Bence Jones proteinuria. The median time from diagnosis to referral was 1.8 months (range, 0-176 months, with 75% referred within 6 months) and 27% had received prior therapy, mostly with melphalan and prednisone. Overall, 32 (68%) patients had renal involvement (21 with nephrotic range proteinuria), 37 (77%) had cardiac involvement (22 with a history of heart failure), 20 (42%) had liver involvement and nine (19%) had neurologic involvement. Patients were not considered ASCT candidates for the following reasons: age 465 years (n ¼ 7), ECOG performance status 43 (n ¼ 2), patients refusal (n ¼ 4), concurrent medical problems (n ¼ 1), systolic blood pressure p90 mmHg (n ¼ 1), uncontrolled cardiac failure (n ¼ 1), multiple organ failure with ECOG o3 and systolic blood pressure X90 mmHg (n ¼ 2), prolonged stable disease (n ¼ 1) or minimal symptoms (n ¼ 2). The 26 patients who were thus deemed transplant candidates were significantly younger (55 vs 63 years, P ¼ 0.001), had a better performance status (96 vs 73% with ECOG score p2, P ¼ 0.02) and had a trend to a better left ventricular ejection fraction (27 vs 45% with EF p50%, P ¼ 0.2) and less syncope (4 vs 18%, P ¼ 0.11).
Peripheral blood stem cell mobilization
Of the 26 transplant candidates, 10 were initially mobilized with cyclophosphamide and G-CSF and 16 were mobilized with G-CSF alone. One patient who failed G-CSF mobilization subsequently mobilized stem cells successfully following cyclophosphamide and G-CSF. Six patients did not proceed to ASCT due to death (n ¼ 5) or inadequate stem cell collection (n ¼ 1). Before January 1999, three of 13 died from progressive disease or disease-related complications during mobilization (cardiac n ¼ 2, hepatic n ¼ 1) and after January 1999, two of 13 died. Of these five patients who died prior to transplantation, all had cardiac AL and an ECOG performance score of 2 or 3, four had a history of heart failure, three had a systolic blood pressure of p90 mmHg and three had an ejection fraction of p50%. Three of these patients were mobilized with cyclophosphamide and G-CSF and two received G-CSF alone. /kg (range, 2.1-13.63). Neutrophils were engrafted by a median of day 11 (range, [10] [11] [12] [13] [14] and platelets by day 12 (range, . The median number of platelet transfusion episodes was 1 (range, 0-7), and a median of 3 units (range, 0-18) of packed cells were transfused. The overall day 100 transplant-related mortality rate was 35%. Since January 1999, when new selection criteria and prophylactic measures were introduced, transplant-related mortality has decreased from 50% (n ¼ 5/10) to 20% (n ¼ 2/ 10). Three patients died around the time of stem cell reinfusion due to acute cardiac events, three patients died on days 28, 31 and 50 from multiorgan failure in the setting of sepsis, and one patients died from progressive cardiac and renal AL on day 85. Other causes of serious early morbidity included transient neurological episodes during stem cell reinfusion, cardiac arrhythmias, fluid retention, renal dysfunction and gastrointestinal bleeding. There have been two late deaths from progressive cardiac AL at 25 and 60 months post-ASCT.
Response to ASCT
Seven of 20 patients died before response assessment and were considered nonresponders. Two patients were not evaluable due to loss to follow-up. Hematologic and organ responses are detailed in Table 2 . Overall, 56% of patients achieved a hematologic response with half of these being complete responses. Of note, 10 patients only had a trace of monoclonal paraprotein pre-transplant. Intent-to-treat organ-specific responses were 46% for renal (n ¼ 6/13), 50% for liver (n ¼ 3/6) and 25% for cardiac (n ¼ 3/12) involvement. No patients were assessable for neurologic response. Response in patients surviving transplant was 75% for renal (n ¼ 6/8), 100% for liver (n ¼ 3/3) and 40% for cardiac (n ¼ 2/5) organ involvement.
Survival after ASCT
The median follow-up of survivors is 18 months. The median overall survival for transplanted patients is 60 months with a 3-year estimated overall survival of 56%. In univariate analysis (Figure 2 ), improved survival was predicted by better ECOG performance status (P ¼ 0.08), normal alkaline phosphatase (P ¼ 0.08), the presence of nephrotic syndrome (P ¼ 0.01) and the absence of severe hypotension (3-year overall survival 0 vs 75% for systolic blood pressure p vs 490 mmHg, P ¼ 0.01). There was no impact of age, prior therapy or number of involved organs on survival. There was a trend to improved outcomes following transplants since January 1999 (P ¼ 0.09, Figure 3 ).
Survival of all referred patients
The median follow-up of all surviving patients is 18 months. The estimated 3-year overall survival of all 48 referred patients (ie transplanted or not) is 44% with a median survival of 40 months. Univariate analysis indicated that poorer survival was predicted by worse ECOG performance status (p2 vs 42, P ¼ 0.001), raised alkaline phosphatase (Po0.001), the absence of nephrotic syndrome (P ¼ 0.06), increased septal wall thickness (P ¼ 0.07), a history of cardiac failure (P ¼ 0.002), a systolic blood pressure of p90 mmHg (Po0.001) and involvement of greater than two organs (P ¼ 0.003). In multivariate analysis, an adverse outcome was associated with poor ECOG performance status (p2 vs 42, P ¼ 0.001), the absence of nephrotic syndrome (P ¼ 0.06), increased septal wall thickness (P ¼ 0.07) and a systolic blood pressure of p90 mmHg (Po0.001). Even though patients considered transplant candidates were younger, had better performance status and less cardiac involvement, this was not reflected in better overall survival for this group (3-year overall survival 42 vs 45% for transplant vs nontransplant candidates, P ¼ NS). 
Discussion
The dismal prognosis associated with AL, especially those with cardiac involvement, 7, 8 has motivated the search for better therapies. Currently, oral melphalan and prednisone can be considered the standard of care, 8 but the median survival of 18 months with only 15% of patients alive at 5 years remains poor. ASCT is currently under evaluation as a therapy with encouraging response rates, but high transplant-related mortality. [13] [14] [15] [16] [17] [18] [19] We and others 16 have demonstrated that ASCT is appropriate only for a subset of patients without advanced cardiac disease. In an attempt to offer ASCT for those patients with the poorest prognosis, particularly cardiac AL, inclusion criteria for our program were initially broad. In spite of this, only 26 of 48 referred patients with AL were considered eligible for ASCT. Furthermore, no ASCT candidate with an ECOG performance score 42 actually progressed to transplant and there were no survivors among the transplanted patients with a systolic blood pressure p90 mmHg. Attempts to optimize the cardiac status of these patients prior to ASCT were ultimately unsuccessful. On the basis of this, we now exclude patients from ASCT if they have ECOG performance status 42 or a systolic blood pressure at referral of p90 mmHg. Reevaluating our cohort on the basis of these new selection criteria, only 17 of 48 (35%) patients referred with AL would be considered eligible for ASCT. Similarly, a recent report from the Boston group 20 states that systolic blood pressure p90 mmHg and oxygen saturation p95% on room air are exclusion criteria for ASCT, although these factors were not listed in their initial reports. 13, 14 A recent review by Comenzo and Gertz 21 has proposed similar exclusions and suggested a risk-adapted strategy to melphalan dosing.
Our findings justify the use of inclusion criteria requiring preserved organ function, but also demonstrate the significant selection bias that impacts most reports of ASCT for AL where patients have preserved performance status and normal renal, hepatic and cardiac function at the time of transplant. Similar to reports of ASCT in other settings, 22 encouraging response rates and outcomes have led to suggestions of improved survival 10 despite a lack of randomized trials. There has been a nonsignificant trend to improved survival in our series (Figure 3 ) simply through the introduction of different selection criteria. This considerable selection bias has also been shown by Dispenzieri et al 11 who demonstrated that eligibility for ASCT is, in itself, a favorable prognostic factor for survival. Considerable morbidity and mortality occurs in the peristem cell collection period and during stem cell infusion, thus treatment-related mortality remains high. Improvements have occurred over time at our institution (transplant-related mortality from 50 to 20%) probably via better patient selection and the implementation of previously published prophylactic recommendations. 12 The high mortality during stem cell collection indicates that specific attention and careful monitoring is required for AL amyloid patients receiving growth factor mobilization (reviewed by Comenzo 21 ). Delaying high-dose therapy also appears to confer an adverse prognosis due to interim disease progression as seen in a randomized trial of pretransplant oral melphalan vs up front ASCT. 23 Several groups have reported on the prognostic significance of the number of organs affected by amyloid deposition on survival following ASCT. 13, 16, 18 Our series did not detect this effect in transplanted patients, but noted similar findings in univariate (but not multivariate) analysis of all 48 referred patients. It is likely that small numbers contributed to this result. Not all organ involvement, however, is associated with a negative outcome. We noted that the presence of nephrotic syndrome predicted an improved survival, a finding consistent with other 13 reports. In the nontransplant setting, nephrotic syndrome also appears to confer better survival. 6, 7 Thus, those with predominantly renal involvement, especially in the absence of cardiac involvement, have the most favorable outcome.
Among transplanted patients, we noted complete hematologic responses in 28% consistent with other reports (range 14-62%). 13, 16, 24, 25 Given that the only evidence of plasma cell dyscrasia in many patients is limited to a trace of serum or urine monoclonal paraprotein, it is difficult to ascribe much significance to hematologic response, although it has been associated with improved overall survival in one study. 24 More important are the organspecific response rates, and ASCT can certainly induce clinically meaningful improvement in organ function in a subset of patients. We observed intent-to-treat responses in 25, 46 and 50% of patients with cardiac, renal and hepatic involvement, respectively. Responses in transplant survivors were greater, confirming the capacity for amyloid resorption if the underlying 'production clone' is eradicated. The assessment of organ responses is difficult and often somewhat subjective. The IBMTR has recently standardized response criteria for these patients to allow more uniform reporting and to facilitate comparison between studies. Scintigraphic imaging with radiolabelled serum amyloid P component provides a semiquantitative assessment of disease progress 26 and may reflect more accurately organ responses to ASCT.
For the time being, therapeutic options for patients with AL remain limited. ASCT is suitable only for a minority of patients, in retrospect, less than half of those referred in our series. Selection of appropriate candidates for transplantation is important and can result in avoidance of excessive transplant-related mortality. Those with significant hypotension (systolic blood pressure p90 mmHg) and poor performance status (ECOG42) have an exceedingly high mortality and should not be transplanted. For those undergoing high-dose therapy, organ response rates appear promising, but overall only small numbers benefit. Conclusive evidence of improved survival for this select group of patients is still lacking and will require randomized trials.
